Company Encyclopedia
View More
name
Esperion Therap
ESPR.US
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co.
4.514 T
ESPR.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking70/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE25.76%A
    • Profit Margin-34.84%E
    • Gross Margin36.52%C
  • Growth ScoreC
    • Revenue YoY2.83%C
    • Net Profit YoY-21.97%D
    • Total Assets YoY15.89%A
    • Net Assets YoY-21.92%E
  • Cash ScoreD
    • Cash Flow Margin-287.06%D
    • OCF YoY2.83%C
  • Operating ScoreB
    • Turnover0.9B
  • Debt ScoreE
    • Gearing Ratio223.99%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Esperion Therapeutics shares are trading higher after Piper Sandler initiated coverage on the stock with an Overweight rating and a $9 price target.

    benzinga_article·
    US
    ESPR
    +0.26%
    benzinga_article·
    US
    ESPR
    +0.26%

    BUZZ-Esperion gains after Piper Sandler initiates with 'overweight' rating

    Esperion Therapeutics shares rise 1.4% after Piper Sandler rates them "overweight" with a $9 price target, citing strong sales potential for its bempedoic acid franchise. The brokerage expects U.S. sales to exceed $650 million, supported by broad labels and payer access. Out of 8 analysts, 6 recommend buying the stock, which is up 44% YTD.

    Reuters·
    US
    ESPR
    +0.26%
    Reuters·
    US
    ESPR
    +0.26%

    Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

    - Company to Receive $90 Million Total Payment ...

    GlobeNewswire·
    US
    ESPR
    +0.26%
    GlobeNewswire·
    US
    ESPR
    +0.26%

    BUZZ-Esperion rises as partner launches cholesterol drug in Japan

    Shares of drug developer Esperionrise 1.7% to $3 premarketCompany says it will receive a $90 million payment after its Japanese partner, Otsuka Pharmaceutical, launched cholesterol-lowering drug Nexletol in Japan.Otsuka received national approval to sell Nexletol for patients with high cholesterol and certain inherited cholesterol disorders, ESPR saysESPR eligible for additional milestones and 15%-30% royalties on Japan salesJapan is third-largest market for cardiovascular prevention, ESPR saysUp to last close, shares up ~34% YTD

    Reuters·
    US
    ESPR
    +0.26%
    US
    OTSKY
    +2.71%
    Reuters·
    US
    ESPR
    +0.26%
    US
    OTSKY
    +2.71%

    Esperion Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

    Esperion Therapeutics Inc. will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025. The company will discuss its progress in developing and commercializing FDA-approved, non-statin, oral medicines for cardiovascular disease patients. This presentation is part of their ongoing efforts as a commercial stage biopharmaceutical company.

    Reuters·
    US
    ESPR
    +0.26%
    Reuters·
    US
    ESPR
    +0.26%
    © 2025 Longbridge｜Disclaimer